Rna Diagnostics hosted a symposium with leading breast cancer researchers and clinical specialists in the UK.
The symposium, chaired by Professor Charles Coombes, Medical Oncology, Imperial College, London on May 22, at the Canadian High Commission in London, brought together leading breast cancer Researchers and Clinical Specialists and members of the Experimental Cancer Medicine Centre (ECMC) team. Discussion, moderated by Professor Rob Coleman, Sheffield focused on the impact of RDA in Personalized Breast Cancer therapy with the goal of generating collaborations with UK clinicians.
“RDA is a needed diagnostic tool for breast cancer chemotherapy management. RDA allows physicians to better determine the most appropriate treatment for their patients,” said Professor Coombes. RDA determines early in a woman’s breast cancer treatment if she is responding to chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatment, avoiding the harmful side-effects of ineffective chemotherapy, improving her outcome.
A featured speaker at the event based on his experience with RDA was Dr. Daniele Generali, of the Instituti Ospitalieri di Cremona, Italy. The symposium generated requests for more RDA data and great interest in collaborations. President and CEO of Rna Diagnostics, Dr. Ken Pritzker said, “Feedback from the UK clinicians was positive and consistent. RDA is the kind of marker they are looking for and it will change breast cancer practice for the better. The implications for patient care were understood right away.”
Rna Diagnostics appreciated the support of the High Commission of Canada in London, specifically Dr. Caroline Martin, Trade Commissioner and her team who assisted in creating a dynamic symposium experience.
At the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 1, RDA continued to generate great interest in discussions with UK clinicians that were not able to attend the London symposium.
About Rna Diagnostics Inc.
Rna Diagnostics is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RNA Disruption Assay™ (RDA™), determines early in a woman’s breast cancer treatment if she is responding to chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatment, avoiding the harmful side-effects of ineffective chemotherapy and thereby improving her outcome. For more information on Rna Diagnostics, please visit www.rnadiagnostics.com
The Experimental Cancer Medicine Centre (ECMC) Network is jointly supported by Cancer Research UK and the health departments for England, Scotland, Wales and Northern Ireland. The goal of the ECMC Network initiative is to drive the development of new therapies to bring benefits to patients faster.